


CD38 inhibitor 1

Cat. No.:	HY-123999		
CAS No.:	1700637-55-3		
Molecular Formula:	C ₂₂ H ₂₇ N ₃ O ₃ S		
Molecular Weight:	413.53		
Target:	CD38		
Pathway:	Immunology/Inflammation		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 25 mg/mL (60.46 mM); ultrasonic and warming and heat to 60°C)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.4182 mL	12.0910 mL	24.1820 mL
	5 mM	0.4836 mL	2.4182 mL	4.8364 mL
	10 mM	0.2418 mL	1.2091 mL	2.4182 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 50% PEG300 >> 50% saline
Solubility: 10 mg/mL (24.18 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: corn oil
Solubility: 10 mg/mL (24.18 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (6.05 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (6.05 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (6.05 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

CD38 inhibitor 1 (compound 78c) is a potent CD38 inhibitor with IC₅₀s of 7.3 nM and 1.9 nM for hCD38 and mouse CD38^[1].

IC₅₀ & Target

IC₅₀: 7.3 nM (hCD38), 1.9 nM (mouse CD38)^[1]

	Ki: 0.3 nM (WT hCD38) ^[1]	
In Vivo	CD38 inhibitor (30 mg/kg; oral administration; 2 and 6 hours) significantly elevates NAD levels in liver and muscle ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Diet induced obese (DIO) C57Bl6 mice ^[1]
	Dosage:	30 mg/kg
	Administration:	Orally once
	Result:	NAD levels were significantly increased at both the 2 and 6 h time points in liver and muscle.

CUSTOMER VALIDATION

- Signal Transduct Target Ther. 2023 Sep 18;8(1):353.
- Cell Metab. 2021 Jan 5;33(1):110-127.e5.
- Brain Behav Immun. 2023 Oct 2;115:64-79.
- Cell Death Dis. 2020 Jan 6;11(1):15.
- Cell Rep. 2022 Dec 13;41(11):111803.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Tarragó MG, Chini CCS, Kanamori KS, et al. A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD⁺ Decline. Cell Metab. 2018;27(5):1081-1095.e10.

[2]. Haffner CD, et al. Discovery, Synthesis, and Biological Evaluation of Thiazoloquin(az)olin(on)es as Potent CD38 Inhibitors. J Med Chem. 2015 Apr 23;58(8):3548-71.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA